RVTY vs TECH
RVTY: Revvity is a global life sciences company that provides the essential tools and services for researchers to accelerate drug discovery and clinicians to deliver more precise diagnostics. TECH: Bio-Techne is a global life science company providing essential reagents, analytical tools, and diagnostic solutions to accelerate biological research and improve disease diagnosis.
Side-by-side fundamentals
| Metric | RVTY | TECH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $152.16 | $72.45 | |
| Market cap | $17.0B | $11.4B | |
| P/E as of 2026-10-08 | 72.41 | 105.00 | RVTY lower |
| Net margin FY2025, SEC XBRL | +8.4% | +6.0% | RVTY higher |
| Gross margin | +72.3% | +65.8% | RVTY higher |
| Operating margin | +12.5% | +20.7% | TECH higher |
| ROE FY2025, SEC XBRL | +3.3% | +3.8% | TECH higher |
| ROA FY2025, SEC XBRL | +2.0% | +2.9% | TECH higher |
| Debt / equity as of 2026-09-02 | 0.44 | 0.10 | TECH lower |
| Revenue growth (YoY) as of 2026-09-02 | +4.0% | +0.2% | RVTY higher |
| Revenue CAGR (3y) SEC XBRL | -9.3% | +2.2% | TECH higher |
| Dividend yield as of 2026-09-02 | +0.2% | +0.4% | TECH higher |
| Dividend streak (yrs) SEC XBRL | 3 | 6 | TECH higher |
| Beta as of 2026-09-02 | 1.10 | 1.07 | |
| 1-year return as of 2026-10-08 close | +65.8% | +19.6% | RVTY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.